SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-076685
Filing Date
2024-06-24
Accepted
2024-06-24 16:00:11
Documents
12
Period of Report
2024-06-20
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K omga-20240620.htm   iXBRL 8-K 83708
2 EX-3.1 omga-ex3_1.htm EX-3.1 73195
  Complete submission text file 0000950170-24-076685.txt   294308

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT omga-20240620.xsd EX-101.SCH 29129
15 EXTRACTED XBRL INSTANCE DOCUMENT omga-20240620_htm.xml XML 5066
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 241064186
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)